ArticleBritish journal of clinical pharmacology2015
Methods and software tools for design evaluation in population pharmacokinetics-pharmacodynamics studies.
Article in British journal of clinical pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Study design and population pharmacokinetic analysis of a phase II dose-ranging study of interleukin-1 receptor antagonist.Journal of pharmacokinetics and pharmacodynamics · 2016Trial
- Advances and Further Comparison of Software Tools for Fisher Information Matrix-Based Design Evaluation in Pharmacometrics.Pharmaceutical research · 2026Article
- Population pharmacokinetics of caspofungin in critically ill Chinese children: a prospective observational study.Antimicrobial agents and chemotherapy · 2026Observational
- Design Optimization for Developing Population Pharmacokinetic Models in Critically Ill Children: Application to Teicoplanin, Piperacillin and Meropenem.Clinical pharmacokinetics · 2026Article
- Optimized Sampling Strategies for Isoniazid in East Asian Pediatric Populations Using Population Pharmacokinetics-Informed Approaches.Drug design, development and therapy · 2025Article
- Bridging systems biology and tissue engineering: Unleashing the full potential of complex 3DBiophysics reviews · 2024Review
- Evaluation of model-based bioequivalence approach for single sample pharmacokinetic studies.CPT: pharmacometrics & systems pharmacology · 2023Article
- NLoed: A Python Package for Nonlinear Optimal Experimental Design in Systems Biology.ACS synthetic biology · 2022Article
- A case-study of model-informed drug development of a novel PCSK9 anti sense oligonucleotide. Part 1: First time in man to phase II.CPT: pharmacometrics & systems pharmacology · 2022Article
- Ethnicity evaluation of ferric pyrophosphate citrate among Asian and Non-Asian populations: a population pharmacokinetics analysis.European journal of clinical pharmacology · 2022Article
- Tutorial for $DESIGN in NONMEM: Clinical trial evaluation and optimization.CPT: pharmacometrics & systems pharmacology · 2021Article
- Metaheuristics for pharmacometrics.CPT: pharmacometrics & systems pharmacology · 2021Review
- Pharmacometric estimation methods for aggregate data, including data simulated from other pharmacometric models.Journal of pharmacokinetics and pharmacodynamics · 2021Article
- Model-based approach to sampling optimization in studies of antibacterial drugs for infants and young children.Clinical and translational science · 2021Article
- Clinical Pharmacokinetics of Oral Sodium Selenite and Dosing Implications in the Treatment of Patients with Metastatic Cancer.Drugs in R&D · 2021Article
- Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis.British journal of clinical pharmacology · 2021Article
- Non-Linear Pharmacokinetics of Oral Roscovitine (Seliciclib) in Cystic Fibrosis Patients Chronically Infected withPharmaceutics · 2020Article
- Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy: the impact of body weight and target on an optimal dosing regimen.The Journal of antimicrobial chemotherapy · 2019Article
- Development of a Parsimonious Design for Optimal Classification of Exclusive Breastfeeding.CPT: pharmacometrics & systems pharmacology · 2019Article
- Pharmacokinetic-Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance.Clinical pharmacokinetics · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Population pharmacokinetic (PK)-pharmacodynamic (PKPD) models are increasingly used in drug development and in academic research; hence, designing efficient studies is an important task. Following the first theoretical work on optimal design for nonlinear mixed-effects models, this research theme has grown rapidly. There are now several different software tools that implement an evaluation of the Fisher information matrix for population PKPD. We compared and evaluated the following five software tools: PFIM, PkStaMp, PopDes, PopED and POPT. The comparisons were performed using two models, a simple-one compartment warfarin PK model and a more complex PKPD model for pegylated interferon, with data on both concentration and response of viral load of hepatitis C virus. The results of the software were compared in terms of the standard error (SE) values of the parameters predicted from the software and the empirical SE values obtained via replicated clinical trial simulation and estimation. For the warfarin PK model and the pegylated interferon PKPD model, all software gave similar results. Interestingly, it was seen, for all software, that the simpler approximation to the Fisher information matrix, using the block diagonal matrix, provided predicted SE values that were closer to the empirical SE values than when the more complicated approximation was used (the full matrix). For most PKPD models, using any of the available software tools will provide meaningful results, avoiding cumbersome simulation and allowing design optimization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.